Cargando…

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials

INTRODUCTION: The adjuvanted recombinant zoster vaccine (RZV) has demonstrated high efficacy against herpes zoster in older adults and immunocompromised populations. We present comprehensive safety data from six clinical trials in immunocompromised populations (autologous hematopoietic stem cell tra...

Descripción completa

Detalles Bibliográficos
Autores principales:	López-Fauqued, Marta, Co-van der Mee, Maribel, Bastidas, Adriana, Beukelaers, Pierre, Dagnew, Alemnew F., Fernandez Garcia, Juan Jose, Schuind, Anne, Tavares-da-Silva, Fernanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217041/ https://www.ncbi.nlm.nih.gov/pubmed/34115324 http://dx.doi.org/10.1007/s40264-021-01076-w

Ejemplares similares

37. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine (RZV) in Immunocompromised Populations: an Overview of 6 Trials
por: Fauqued, Marta Lopez, et al.
Publicado: (2020)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
por: Dagnew, Alemnew F., et al.
Publicado: (2021)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

2776. Post-marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Review of Spontaneous Reports Since Introduction
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2019)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials
por: Kim, Joon Hyung, et al.
Publicado: (2023)

Efficacy and serious adverse events profile of the adjuvanted recombinant zoster vaccine in adults with pre-existing potential immune-mediated diseases: a pooled post hoc analysis on two parallel randomized trials
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

7. Can Recombinant Zoster Vaccine Administration Decrease the Use of Herpes Zoster-related Pain Medication Across Randomized Controlled Studies?
por: Kim, Joon Hyung, et al.
Publicado: (2020)

An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine
por: Pirrotta, Paola, et al.
Publicado: (2021)

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
por: Fiore, Joseph, et al.
Publicado: (2021)

2905. Long-term Immunological Persistence of the Adjuvanted Recombinant Zoster Vaccine: Clinical Data and Mathematical Modeling
por: Bastidas, Adriana, et al.
Publicado: (2019)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020)

149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial
por: Dagnew, Alemnew F, et al.
Publicado: (2018)

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
por: Stadtmauer, Edward A., et al.
Publicado: (2021)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

Varicella Zoster Virus-Specific Hyperimmunoglobulin in the Adjuvant Treatment of Immunocompromised Herpes Zoster Patients: A Case Series
por: Terheyden, Patrick, et al.
Publicado: (2023)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Public health impact of recombinant zoster vaccine for prevention of herpes zoster in US adults immunocompromised due to cancer
por: Curran, Desmond, et al.
Publicado: (2023)

Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies
por: Mwakingwe-Omari, Agnes, et al.
Publicado: (2023)

Results of a Safety Pooled Analysis of an Adjuvanted Herpes Zoster Subunit Vaccine in More than 14,500 Participants Aged 50 Years or Older
por: López-Fauqued, Marta, et al.
Publicado: (2017)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
por: Kim, Joon Hyung, et al.
Publicado: (2021)

Central nervous system varicella zoster vasculopathy in an immunocompromised patient
por: Guedes, Mariana, et al.
Publicado: (2018)

Herpetic zoster folliculitis in the immunocompromised host
por: Shaigany, Sheila, et al.
Publicado: (2015)

Multidermatomal Herpes Zoster in immunocompromised patient
por: Park, Keon Woo, et al.
Publicado: (2020)

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
por: Vink, Peter, et al.
Publicado: (2019)

2778. Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine
por: Schmader, Kenneth E, et al.
Publicado: (2019)

2779. Efficacy of the Adjuvanted Recombinant Zoster Vaccine According to Sex, Geographic Region, and Geographic Ancestry/Ethnicity: A Post-hoc Analysis
por: Willer, David O, et al.
Publicado: (2019)

2780. Reactogenicity Profile of Adjuvanted Recombinant Zoster Vaccine after Dose 2 According to the Intensity of the Same Event Experienced after Dose 1
por: Colindres, Romulo, et al.
Publicado: (2019)

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials
por: Colindres, Romulo, et al.
Publicado: (2020)

Preventing varicella zoster infection in immunocompromised adults with varicella zoster–specific immunoglobulins
por: Gelman, Daniel, et al.
Publicado: (2023)

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals
por: Curran, Desmond, et al.
Publicado: (2020)

Immunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Chronically Immunosuppressed Adults Following Renal Transplant: A Phase 3, Randomized Clinical Trial
por: Vink, Peter, et al.
Publicado: (2020)

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
por: Oostvogels, Lidia, et al.
Publicado: (2019)

1956. Persistence of Immune Response and Safety of an Adjuvanted Recombinant Zoster Vaccine in Older Adults Previously Vaccinated with a Live-Attenuated Herpes Zoster Vaccine: End-of-Study Results of a Phase III, Group-Matched, Clinical Trial
por: Mrkvan, Tomas, et al.
Publicado: (2018)

Herpes-Zoster-Associated Voiding Dysfunction in an Immunocompromised Patient
por: Alalwan, Adel A, et al.
Publicado: (2020)

Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older
por: Schwarz, Tino F, et al.
Publicado: (2017)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

No Consistent Evidence of Decreased Exposure to Varicella-Zoster Virus Among Older Adults in Countries with Universal Varicella Vaccination
por: Carryn, Stephane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rjlhdjjmudgpdo4j73dp6n6j30